Marker Therapeutics (MRKR) Change in Accured Expenses (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Change in Accured Expenses of $614301.0 for Q1 2026, up 82.77% year-over-year from $336114.0 in Q1 2025, and up 268.18% quarter-over-quarter from -$365263.0 in Q4 2025.
Marker Therapeutics (MRKR) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Change in Accured Expenses for 17 consecutive years, with $614301.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 82.77% year-over-year to $614301.0; the TTM figure through Mar 2026 stood at -$176383.0 (down 225.66% YoY), while the FY2025 annual figure was -$454570.0, down 5288.56% from the prior year.
- Change in Accured Expenses climbed to $614301.0 in Q1 2026 per MRKR's latest filing, from -$365263.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.9 million in Q2 2022 and bottomed at -$4.0 million in Q1 2022.
- Historically, Change in Accured Expenses has averaged -$109977.1 across 5 years, with a median of $85859.0 in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 346.12% in 2024 and fell as far as 414.5% in 2024.
- Marker Therapeutics' Change in Accured Expenses stood at -$1.0 million in 2022, then surged by 45.77% to -$558826.0 in 2023, then sank by 43.76% to -$803381.0 in 2024, then soared by 54.53% to -$365263.0 in 2025, then surged by 268.18% to $614301.0 in 2026.
- Business Quant data shows MRKR's Change in Accured Expenses at $614301.0 in Q1 2026, -$365263.0 in Q4 2025, and -$603224.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | -889,768.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 614,301.00 |
| Mar 31, 2026 | 614,301.00 |
| Dec 31, 2025 | -365,263.00 |
| Dec 31, 2025 | -365,263.00 |
| Sep 30, 2025 | -603,224.00 |
| Sep 30, 2025 | -603,224.00 |
| Jun 30, 2025 | 177,803.00 |
| Jun 30, 2025 | 177,803.00 |
| Mar 31, 2025 | 336,114.00 |
| Mar 31, 2025 | 336,114.00 |
| Dec 31, 2024 | -803,381.00 |
| Dec 31, 2024 | -803,381.00 |
| Sep 30, 2024 | 877,663.00 |
| Sep 30, 2024 | 877,663.00 |
| Jun 30, 2024 | -270,028.00 |
| Jun 30, 2024 | -270,028.00 |
| Mar 31, 2024 | 204,507.00 |
| Mar 31, 2024 | 204,507.00 |
| Dec 31, 2023 | -558,826.00 |
| Dec 31, 2023 | -558,826.00 |